Prevention and inhibition of TC-1 cell growth in tumor bearing mice by HPV16 E7 protein in fusion with Shiga toxin B-subunit from Shigella dysenteriae

Cell Journal

Volumn 15, Issue 2, 2013, Pages 176-181

  Sadraeian, Mohammad ^a   Khoshnood Mansoorkhani, Mohammad Javad ^b   Mohkam, Milad ^a,b   Rasoul Amini, Sara ^a,b   Hesaraki, Mahdi ^c   Ghasemi, Younes ^a,b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ROYAN INSTITUTE FOR REPRODUCTIVE BIOMEDICINE   (Iran)

Author keywords

Cervical cancer; E7 STxB; Immunization; Protein vaccine; Tumor growth

Indexed keywords

HYBRID PROTEIN; PEPTIDE VACCINE; PROTEIN E7; RECOMBINANT PROTEIN; SHIGA TOXIN; SHIGA TOXIN B SUBUNIT; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER GROWTH; CANCER IMMUNIZATION; CANCER INCIDENCE; CANCER INHIBITION; CANCER PREVENTION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; LUNG; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN DETERMINATION; SHIGELLA DYSENTERIAE; TUMOR IMMUNITY; TUMOR MODEL; TUMOR VOLUME; UTERINE CERVIX CANCER; WESTERN BLOTTING;

EID: 84907812414     PISSN: 22285806     EISSN: 22285814     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Bosch FX, Lorincz A, Muñoz N, Meijer C, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002; 55(4): 244-265.
2. Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995; 87(11): 796-802.
3. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001; 37 Suppl 8: S4-S66.
4. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189(1): 12-19.
5. DeFilippis RA, Goodwin EC, Wu L, DiMaio D. Endogenous human papillomavirus E6 and E7 proteins differentially regulate proliferation, senescence, and apoptosis in HeLa cervical carcinoma cells. J Virol. 2003; 77 (2): 1551-1563.
6. Fazeli M, Soleymanjahi H, Ghaemi A, Farzanehpour M, Amanzadeh A, Hashemi R. Efficacy of HPV-16 E7 based vaccine in a TC-1 tumoric animal model of cervical cancer. Cell J. 2011; 12 (4): 483-488.
7. Govan VA. Strategies for human papillomavirus therapeutic vaccines and other therapies based on the E6 and E7 oncogenes. Ann NY Acad Sci. 2005; 1056(1): 328-343.
8. Li YL, Qiu XH, Shen C, Liu JN, Zhang J. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors. Oncol Rep. 2010; 24(5): 1323-1329.
9. Hallez S, Simon P, Maudoux F, Doyen J, Noel JC, Beliard A, et al. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia. Cancer Immunol Immunother. 2004; 53(7): 642-650.
10. Wang H, Griffiths MN, Burton DR, Ghazal P. Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization. Proc Natl Acad Sci. 2000; 97(2): 847-852.
11. Haicheur N, Benchetrit F, Amessou M, Leclerc C, Falguières T, Fayolle C, et al. The B subunit of Shiga toxin coupled to full-size antigenic protein elicits humoral and cell-mediated immune responses associated with a Th1-dominant polarization. Int Immunol. 2003; 15(10): 1161-1171.
12. Pina DG, Johannes L. Cholera and Shiga toxin B-subunits: thermodynamic and structural considerations for function and biomedical applications. Toxicon. 2005; 45(4): 389-393.
13. Haicheur N, Bismuth E, Bosset S, Adotevi O, Warnier G, Lacabanne V, et al. The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens. J Immunol. 2000; 165(6): 3301-3308.
14. Sakiri R, Ramegowda B, Tesh VL. Shiga toxin type 1 activates tumor necrosis factor alpha gene transcription and nuclear translocation of the transcriptional activators nuclear factor kappa B and activator protein-1. Blood. 1998; 92(2): 558-566.
15. Vingert B, Adotevi O, Patin D, Jung S, Shrikant P, Freyburger L, et al. The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity. Eur J Immunol. 2006; 36 (5): 1124-1135.
16. Ji H, Chang EY, Lin KY, Kurman RJ, Pardoll DM, Wu TC. Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. Int J Cancer. 1998; 78(1): 41-45.
17. Sadraeian M, Honari H, Madanchi H, Hesaraki M. Extraction, cloning and expression of RTB, as a vaccine adjuvant/carrier, in E. coli and production of mouse polyclonal antibody (anti-B chain Abs). Iran J Pharm Sci. 2011; 7(4): 247-254.
18. Sadraeian M, Honari H, Madanchi H, Hesaraki M. Cloning and expression of CtxB-StxB in Esherichia coli: a challenge for improvement of immune response against StxB. Iran J Pharm Sci. 2011; 7(3): 185-190.
19. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 1996; 56(1): 21-26.
20. Sadraeian M, Ghoshoon MB, Mohkam M, Karimi Z, Rasoul-Amini S, Ghasemi Y. Modification in media composition to obtain secretory production of STxB-based vaccines using Escherichia coli. Virol Sin. 2013; 28(1): 43-48.